Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI)

Subjects

Subjects :

Dermatology

Details

ISSN :

25741624

Volume :

7

Database :

OpenAIRE

Journal :

SKIN The Journal of Cutaneous Medicine

Accession number :

edsair.doi...........d9a6b122745751e32d727f72696cf42d

Full Text :

https://doi.org/10.25251/skin.7.supp.120